APA (7th ed.) Citation

Fizazi, K., Azad, A. A., Matsubara, N., Carles, J., Fay, A. P., Giorgi, U. d., . . . Agarwal, N. (2024). Publisher correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer : the phase 3 TALAPRO-2 trial. Nature medicine, 30(5), . https://doi.org/10.1038/s41591-024-02835-9

Chicago Style (17th ed.) Citation

Fizazi, Karim, et al. "Publisher Correction: First-line Talazoparib with Enzalutamide in HRR-deficient Metastatic Castration-resistant Prostate Cancer : The Phase 3 TALAPRO-2 Trial." Nature Medicine 30, no. 5 (2024). https://doi.org/10.1038/s41591-024-02835-9.

MLA (9th ed.) Citation

Fizazi, Karim, et al. "Publisher Correction: First-line Talazoparib with Enzalutamide in HRR-deficient Metastatic Castration-resistant Prostate Cancer : The Phase 3 TALAPRO-2 Trial." Nature Medicine, vol. 30, no. 5, 2024, https://doi.org/10.1038/s41591-024-02835-9.